Q-omics provides the consensus-scored RBMY1KP profile across patient tissues and cancer cell-line models. RBMY1KP expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RBMY1KP is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, RBMY1KP RNA expression shows 4,578 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, LUAD, and STAD as cancer lineages where RBMY1KP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMY1KP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMY1KP survival associations across molecular data types. RBMY1KP RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMY1KP RNA expression–survival associations across cancer types. High RBMY1KP expression shows unfavorable associations in UCEC, LUSC, THCA, SKCM, LUAD and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RBMY1KP RNA expression.
This table summarizes RBMY1KP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RBMY1KP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMY1KP shows lower tumor expression in LUAD and LUSC. The LUAD box plot shows higher RBMY1KP RNA expression in normal versus tumor tissue (log2 FC = −0.991, t-test p < 0.001).
This table shows molecular features associated with RBMY1KP in patient tissues and cancer cell lines. In patient samples, RBMY1KP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
